Market Size of Bovine Mastitis Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bovine Mastitis Market Analysis
The bovine mastitis market is projected to register a CAGR of 5.1% during the forecast period.
The COVID-19 pandemic had an unprecedented impact on the growth of the bovine mastitis market. In 2020, it significantly impacted the supply chain of products for the treatment of bovine mastitis. Containment measures, such as lockdowns and social distancing, created problems in terms of the availability of medicines due to reduced operations in veterinary pharmacies. However, the relaxation of strict regulations post the pandemic led to the normal functioning of supply chain, which contributed to the market's growth.
The major factors responsible for the growth of the bovine mastitis market include the rising incidences of disease, the increasing product launches for animal healthcare, and technological advancements in the field of drug discovery and development.
Bovine mastitis is one of the major concerns in the dairy industry worldwide. Dairy farmers are facing huge economic losses with the rising incidences of cattle death globally. For instance, as per the data published by the MSD Manual in October 2022, severe mastitis caused by coliforms results in an higher incidence of cow death (30-50%) worldwide. These mortality rates in cows increase the direct and indirect costs, such as diagnostics, milk loss, veterinary services, labor, future milk production losses, and therapeutics. The rising bovine mastitis cases and related market loss are fuelling the demand for antibiotics in the treatment of the condition.
The increasing investments in the development of bovine mastitis treatment are expected to contribute to the market's growth. For instance, in August 2021, Stonehaven Incubates invested in the Anifera to conduct additional studies to explore the impact and effectiveness of adjunct therapy in bovine mastitis.
However, the rising threat of antibiotic resistance and a lack of awareness about the disease are expected to slow the market's growth over the forecast period.
